Steven Leonard Chapman Sells 1,698 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 1,698 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $320.99, for a total transaction of $545,041.02. Following the transaction, the chief executive officer directly owned 98,199 shares of the company’s stock, valued at approximately $31,520,897.01. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The shares were sold at an average price of $266.39, for a total transaction of $819,415.64.
• On Tuesday, July 28th, Steven Chapman sold 3,580 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $909,570.60.
• On Monday, July 27th, Steven Chapman sold 2,190 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $570,473.10.

Natera Stock Up 0.2%

Shares of Natera stock opened at $328.18 on Friday. The business has a 50-day moving average price of $292.62 and a 200 day moving average price of $237.63. Natera, Inc. has a fifty-two week low of $157.43 and a fifty-two week high of $343.18. The firm has a market cap of $47.30 billion, a P/E ratio of -241.31 and a beta of 1.54.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same quarter last year, the firm earned ($0.74) EPS. The business’s revenue was up 37.7% on a year-over-year basis. As a group, equities research analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Natera from $315.00 to $360.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Leerink Partners set a $330.00 price objective on shares of Natera in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Guggenheim raised their target price on shares of Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, BTIG Research lifted their target price on Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $319.38.

Institutional Investors Weigh In On Natera

Large investors have recently made changes to their positions in the company. Horizon Investments LLC lifted its stake in shares of Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares during the period. Parallel Advisors LLC increased its stake in shares of Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 47 shares during the period. Raiffeisen Bank International AG raised its holdings in Natera by 48.5% during the second quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company’s stock worth $41,000 after purchasing an additional 49 shares in the last quarter. First Horizon Corp raised its holdings in Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after purchasing an additional 51 shares in the last quarter. Finally, Siemens Fonds Invest GmbH lifted its position in Natera by 3.1% in the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after purchasing an additional 54 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.